Login to Your Account

Other News To Note

Wednesday, June 12, 2013

• Santhera Pharmaceuticals AG, of Liestal, Switzerland, said it obtained an exclusive license from the National Institutes of Health (NIH) to rights on a patent granted in the U.S. for the use of idebenone for the treatment of primary aggressive multiple sclerosis.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription